Immunic's Vidofludimus Calcium Shows Promise for Progressive MS at ECTRIMS 2025

Immunic Showcases Promising Data for Vidofludimus Calcium at ECTRIMS 2025

Immunic, Inc., a biotechnology company specializing in oral small molecule therapies for chronic inflammatory and autoimmune diseases, recently presents compelling results at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona. The showcased data primarily focus on their lead compound, vidofludimus calcium (IMU-838), particularly from the Phase 2 CALLIPER trial, which targets progressive multiple sclerosis (PMS). The trial results reveal a statistically significant enhancement in confirmed disability after 24 weeks of treatment, with the drug demonstrating over a two-fold probability of efficacy compared to placebo within the overall study population. This breakthrough signifies a potential shift in treatment paradigms for patients grappling with PMS, a condition with substantial unmet medical needs.

The CALLIPER trial not only highlights the efficacy of vidofludimus calcium but also shows encouraging results across various patient subgroups. Notably, patients without focal inflammation exhibit signs of slowed disability progression, reinforcing the neuroprotective properties of the drug. These findings are particularly crucial considering the lack of effective treatment options currently available for PMS. The data's inclusion in the Best of ECTRIMS 2025 slide deck underscores its significance in the ongoing discourse around effective therapies for patients suffering from this debilitating condition.

In addition to the CALLIPER trial, Immunic shares long-term data from the Phase 2 EMPhASIS trial, which focuses on relapsing-remitting multiple sclerosis. This trial reveals high rates of patients remaining free from confirmed disability worsening at 12 and 24 weeks, accompanied by low discontinuation rates and a favorable long-term safety profile. Dr. Daniel Vitt, CEO of Immunic, emphasizes the importance of these results, positioning vidofludimus calcium as a transformative option in the oral MS therapy landscape. The data presented at ECTRIMS reaffirms Immunic's commitment to addressing the needs of patients with chronic inflammatory diseases.

As the clinical landscape for multiple sclerosis evolves, Immunic’s advancements in oral therapies could play a pivotal role in the treatment strategies for both PMS and relapsing-remitting forms of the disease. The promising results of vidofludimus calcium not only highlight the potential for improved patient outcomes but also signal a shift towards more effective treatment paradigms in the realm of autoimmune disorders.

Immunic's presence at ECTRIMS is a testament to its dedication to innovation in the field of neurology. The comprehensive data presented at the conference positions the company as a key player in the development of therapies aimed at improving the quality of life for patients facing chronic inflammatory and autoimmune challenges. For further details, Immunic has made the presentations available on its website, encouraging stakeholders to review the significant findings.